Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

Key Takeaways

• 74% average nodule volume reduction at 15‑22 months
• No nodule regrowth observed during follow‑up
• 100% cosmetic, 95% overall patient satisfaction
• No serious adverse events or intranodular fibrosis
• Study included 21 patients, confirming long‑term durability

Summary

Pulse Biosciences reported long‑term results from its first‑in‑human nPulse Vybrance study, showing an average 74% reduction in benign thyroid nodule volume after 15‑22 months. The data, presented at the 2026 North American Society for Interventional Thyroidology meeting, revealed no nodule regrowth, no serious adverse events, and high patient satisfaction. The findings highlight the durability of nanosecond pulsed field ablation (nsPFA) as a non‑thermal alternative to conventional thermal ablation techniques. The study followed 21 patients through extended monitoring to confirm sustained outcomes.

Pulse Analysis

Thyroid nodules affect millions worldwide, and current treatments—radiofrequency, laser, or ethanol ablation—rely on heat, which can damage surrounding tissue and cause variable outcomes. Pulse Biosciences’ nanosecond pulsed field ablation (nsPFA) delivers ultra‑short electrical bursts that selectively disrupt cellular membranes while sparing adjacent structures, offering a fundamentally different, non‑thermal mechanism. This technology aligns with a broader shift toward bio‑electric medicine, where precision energy delivery aims to improve efficacy and reduce collateral injury.

The recent first‑in‑human durability study provides compelling evidence that nsPFA can achieve lasting volume reduction. An average 74% shrinkage persisted up to 22 months, with no evidence of regrowth or intranodular fibrosis, and a safety profile free of serious adverse events. Patient‑reported satisfaction was near‑perfect, underscoring both cosmetic and functional benefits. Compared with thermal ablation, which often requires multiple sessions and carries risks of nerve injury, nsPFA’s single‑session durability could streamline care pathways and lower overall treatment costs.

From a commercial perspective, these results could accelerate regulatory clearance and market adoption, especially as clinicians seek alternatives that minimize downtime and complications. Pulse’s roadmap includes expanding nsPFA into atrial fibrillation and other soft‑tissue applications, suggesting a platform technology with multiple revenue streams. Investors will watch the upcoming second‑half‑2026 data releases closely, as they will clarify the company’s ability to translate early feasibility into broader clinical adoption and sustainable growth.